Immune checkpoint therapy regulates endothelial cell functions and reverses the immunosuppressive effects of VEGF in metastatic melanoma by decreasing intratumoral VEGF(R2) expression and consecutively activating CD8 + T cells via the IFNγ signalling pathway [17,18,41]. This evidence concerns the gene VEGFA and metastatic melanoma.